Handbook of Clinical medicine
KEYWORDS: patient, disease, patients, history, pain, heart, symptoms, ask, time, treatment, risk, examination, aortic, iinnddbb, pulse

Indication Considerations Lipopeptides Vancomycin Complicated Gram +ve Dose IV to trough serum concentration. SEs: Teicoplanin including MRSA. Oral for C. nephrotoxic (monitor creatinine, care with diffi cile (not absorbed). other nephrotoxics) ototoxic, plts. Polymyxins Colistin, Multi-resistant Gram Ωve. Nephrotoxicity in ~50%. Inhaled colistin for polymyxin B ventilator-associated pneumonia. __OOHHCCMM__1100ee..iinnddbb 338866 0022//0055//22001177 1199::0077 sesaesid suoitcefnI Table 9.7 Inhibitors of protein synthesis 387 Antibiotic Indications Considerations Aminoglycosides Gentamicin Gram Ωve infection (activity SEs: nephrotoxic (monitor drug Tobramycin against most Gram +ve and levels and serum creatinine), anaerobes). Tobramycin has vestibular toxicity, ototoxicity. Amikacin activity against Pseudomonas. Amikacin has least resistance. Macrolides Azithromycin Gram +ve cocci (not enterococci SEs ( with erythromycin): GI, Clarithromycin and staphylococci), syphilis, chla- cholestasis, QT. Erythromycin mydia. Cytochrome P450 inhibition ( with azithromycin): warfarin, rhabdomyolysis with statins, calcineurin inhibitor levels. Tetracyclines and derivatives Tetracycline Exacerbation COPD, chlamydia, CI: pregnancy, <8y (teeth/bones). Lyme disease, mycoplasma, rick- SEs: N&V, C. diffi cile, fatty liver, Doxycycline ettsiae, brucella, anthrax, syphi- idiopathic intracranial hyperten- lis, MRSA, malaria prophylaxis. sion. Tigecycline Gram +ve and Gram Ωve includ- Dose adjust in liver dysfunction. ing -lactam-resistant strains. SEs: N&V, photosensitivity, LFTs. Other Clindamycin Gram +ve cocci (not enterococci),  risk C. diffi cile. MRSA, anaerobes.
